Trials / Terminated
TerminatedNCT00903656
Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the potential of a Lapatinib plus Caelyx combination therapy as an effective and safe therapeutic regimen with a favourable cardiotoxicity profile, in the treatment of metastatic breast cancer following failure of prior trastuzumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | doxorubicinhydrochloride, Lapatinib | Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2009-05-18
- Last updated
- 2013-12-24
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00903656. Inclusion in this directory is not an endorsement.